RASHEL GOODKIN, MD
Dermatology Physician in WELLESLEY, Massachusetts. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.
What the federal data shows
RASHEL GOODKIN, MD filed 989 Medicare Part D claims in 2023 as a Dermatology Physician in WELLESLEY, Massachusetts, prescribing 87% generic.
- 989
- Part D claims, 2023
- 87%
- generic prescribing
- $177.4
- industry payments (Sunshine Act)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.
RASHEL GOODKIN, MD's Medicare Part D volume vs every U.S. prescriber
Total Medicare Part D claims, 2023 — across all CMS prescribers nationally
989 Top 25% higher than 75% of 1,370,886 prescribers
Each bar is a band; taller bars hold more prescribers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Medicare Part D Prescriber Public Use File · 2023
RASHEL GOODKIN, MD practices in an ABMS-board-eligible specialty but we don't have enough CMS-participation signals to confirm active board-certified status. Consult CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about RASHEL GOODKIN, MD?
Quality data not reportedPrimary specialty
Medicare Part D claims
Specialty distribution in Massachusetts
How Dermatology Physician compares to other specialties among Massachusetts providers
Dermatology Physician share within Massachusetts
Dermatology Physician is one of the more visible NUCC categories in Massachusetts
Each bar reflects the share of in-state providers whose primary NUCC taxonomy matches the specialty. Long tail of ~690 NUCC codes folded into "Other" to keep the comparison legible.
Specialty board-certification context
Estimated specialty board-certified rate — Dermatology Physician (ABMS / AOA reference)
- Est. board-certified rate
- 78%
- Dermatology Physician ABMS/AOA estimate
Est. board-certified rate (Dermatology Physician) — ABMS / AOA estimate
Verify credentials
- Verify via ABMS free public lookup
- Verify via AOA osteopathic boards
- Specialty volume Dermatology Physician US NPIs
Specialty board-certified rate — Dermatology Physician estimate
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus Maintenance of Certification cycles. CMS does not publish a per-provider board-certification field; the figure shown is the specialty-level estimated rate from ABMS / AOA reference data.
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
RASHEL GOODKIN, MD appears in the CMS NPPES registry as a Dermatology Physician provider holding MD credentials at 10 LAUREL AVE, WELLESLEY, MA, 02481, with a listed phone of (781) 235-8155. NPI 1326057449 was issued on 08/07/2006. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what GOODKIN most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.
Medicare Part D records for calendar year 2023 show 989 prescription claims written by this provider, covering 355 Medicare beneficiaries and totaling roughly $311K in drug spend, split 13% brand-name and 87% generic by claim count. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy.
Dermatology Physician is a mid-sized specialty nationwide, with 14,610 enrolled providers across 53 states and an average of 729 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1326057449 |
|---|---|
| Specialty | Dermatology Physician |
| Credentials | MD |
| Gender | Female |
| NPI Issued | 08/07/2006 |
Verify this provider's license
PlainDoctor pulls this profile from the CMS NPPES public registry. Confirm RASHEL GOODKIN, MD's current license status, disciplinary history, and board certifications with the Massachusetts Board of Registration in Medicine in Massachusetts before relying on this page for a clinical or care decision.
How we sourced this profile
Industry payments received (2024) — CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for RASHEL GOODKIN, MD. Source: openpaymentsdata.cms.gov.
Total received
$177
Largest payer
ABBVIE INC.
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
License & disciplinary context — Massachusetts BORIM 2023 annual report
Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~38K Massachusetts medical licensees in 2023 — they are NOT specific to RASHEL GOODKIN, MD. To verify RASHEL GOODKIN, MD's current license status, search the BORIM public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
BORIM publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the Massachusetts disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Typical
13% brand-name claims vs 87% generic, on 989 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
Prescribing Breakdown
- 30-Day Fills
- 1,150
- Total Day Supply
- 30,325
- Brand vs Generic
- 13% brand / 87% generic
- Brand Drug Cost
- $272K
- Generic Drug Cost
- $39K
- Antibiotic Claims
- 18
Patient Demographics
- Average Patient Age
- 75.3 years
- Avg HCC Risk Score
- 0.98
- Gender Split
- 61% female / 39% male
- Age Distribution
- <65: 16, 65-74: 157, 75-84: 132, 85+: 50
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What RASHEL GOODKIN, MD prescribes most
Top Medicare Part D drugs by claim count, 2023
- Ketoconazole
Ketoconazole
251 claims
- Triamcinolone Acet… 100
Triamcinolone Acetonide
100 claims
- Betamethasone Vale… 84
Betamethasone Valerate
84 claims
- Tacrolimus 70
Tacrolimus
70 claims
- Fluorouracil 65
Fluorouracil
65 claims
- Halobetasol Propio… 55
Halobetasol Propionate
55 claims
- Clindamycin Phosph… 52
Clindamycin Phosphate
52 claims
- Clobetasol Propion… 47
Clobetasol Propionate
47 claims
| Drug | Claims |
|---|---|
| Ketoconazole | 251 |
| Triamcinolone Acetonide | 100 |
| Betamethasone Valerate | 84 |
| Tacrolimus | 70 |
| Fluorouracil | 65 |
| Halobetasol Propionate | 55 |
| Clindamycin Phosphate | 52 |
| Clobetasol Propionate | 47 |
| Jublia Efinaconazole | 38 |
| Calcipotriene | 26 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Dermatology Physician Overview
How RASHEL GOODKIN, MD fits within the Dermatology Physician landscape nationally.
RASHEL GOODKIN, MD's 989 claims are above the specialty average of 729.
Nearby Dermatology Physician Providers in Massachusetts
Other clinicians with the same primary specialty enrolled in Massachusetts, drawn from the same CMS NPPES roster as GOODKIN.
Compare Dermatology Physician nationally: see state-by-state distribution →
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
Explore Massachusetts
Frequently Asked Questions
What is RASHEL GOODKIN, MD's specialty? ▼
How much does RASHEL GOODKIN, MD prescribe under Medicare Part D? ▼
Where is RASHEL GOODKIN, MD located? ▼
What is RASHEL GOODKIN, MD's NPI number? ▼
Does RASHEL GOODKIN, MD prescribe more brand-name or generic drugs? ▼
How many Dermatology Physician providers are there in the US? ▼
What drugs does RASHEL GOODKIN, MD prescribe most often? ▼
Does RASHEL GOODKIN, MD accept Medicare? ▼
How can I verify RASHEL GOODKIN, MD's credentials? ▼
Data Sources
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology